Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5574572 | 0.98 | PTGDR2 (0.47) | PTGDR2FFAR1EPAS1PPARGPPARA | |
| SCHEMBL5574574 | 0.93 | PTGDR2 (0.45) | PTGDR2FFAR1EPAS1PPARGPPARA | |
| SCHEMBL2393357 | 0.89 | PTGDR2 (0.43) | PTGDR2EPAS1VEGFAMRGPRX4LRRK2 | |
| SCHEMBL2393446 | 0.85 | PPARG (0.47) | PTGDR2FFAR1EPAS1PPARGPPARA | |
| SCHEMBL2398431 | 0.84 | MRGPRX4 (0.46) | PTGDR2EPAS1VEGFATRPV1MRGPRX4 | |
| SCHEMBL2395800 | 0.77 | EPAS1 (0.46) | PTGDR2EPAS1VEGFAMRGPRX4LRRK2 | |
| SCHEMBL2393359 | 0.75 | PTGDR2 (0.46) | PTGDR2FFAR1EPAS1VEGFAMRGPRX4 | |
| SCHEMBL2394657 | 0.75 | EPAS1 (0.46) | PTGDR2EPAS1VEGFAMRGPRX4P2RY1 | |
| SCHEMBL5570087 | 0.73 | EPAS1 (0.42) | PTGDR2EPAS1VEGFAMRGPRX4HTR2A | |
| SCHEMBL891091 | 0.73 | L3MBTL1 (0.65) | PTGDR2EPAS1VEGFAMRGPRX4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | PTGDR2 176/4885FFAR1 23/4885EPAS1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.